並列タイトル等高リスク前立腺癌に対する外照射併用高線量率組織内照射と外照射単独の比較検討
一般注記We aimed to compare the outcomes of high-dose-rate brachytherapy (HDR-BT) boost and external beam radiation therapy (EBRT) alone for high-risk prostate cancer. This was a single-center, retrospective, and observational study. Consecutive patients who underwent initial radical treatment by HDR-BT boost or EBRT alone from June 2009 to May 2016 at the Niigata University Medical and Dental Hospital, Japan were included. A total of 96 patients underwent HDR-BT boost, and 61 underwent EBRT alone. The prescription dose of HDR-BT boost was set to 18 Gy/2 times/day with EBRT 39 Gy/13 fractions. The dose for EBRT alone was mostly 70 Gy/28 fractions. The high-risk group received >6 months of prior androgen deprivation therapy. Overall survival, biochemical-free survival, local control, and distant metastasis-free survival rates at 5 years were analyzed. The incidence of urological and gastrointestinal late adverse events of G2 and above was also summarized. In the National Comprehensive Cancer Network (NCCN) high-risk, HDR-BT boost had a significantly higher biochemical-free survival rate at 5 years (98.9% vs 90.7%, p = 0.04). Urethral strictures were more common in the HDR-BT boost group. We will continuously observe the progress of the study patients and determine the longer-term results.
Journal of Radiation Research. 2021, 62(3), 525–532.
新大院博(医)第979号
コレクション（個別）国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文
受理日（W3CDTF）2022-05-09T11:57:37+09:00
連携機関・データベース国立国会図書館 : 国立国会図書館デジタルコレクション